The landmark JDRF continuous glucose monitoring randomized trials: A look back at the accumulated evidence

William V. Tamborlane, Roy W. Beck, Lori Laffel, Katrina J. Ruedy, H. Peter Chase, Rosanna Fiallo-Scharer, Laurel Messer, Victoria Gage, Patricia Burdick, Kerry Milaszewski, Katherine Pratt, Elise Bismuth, Joyce Keady, Margie Lawlor, Bruce Buckingham, Darrell M. Wilson, Jennifer Block, Kari Benassi, Eva Tsalikian, Michael TanseyDebra Kucera, Julie Coffey, Joanne Cabbage, Howard Wolpert, Greeshma Shetty, Astrid Atakov-Castillo, Judith Giusti, Stacey O'Donnell, Suzanne Ghiloni, Irl B. Hirsch, Lisa K. Gilliam, Kathy Fitzpatrick, Dori Khakpour, Tim Wysocki, Larry A. Fox, Nelly Mauras, Kimberly Englert, Joe Permuy, Bruce W. Bode, Kelli O'Neil, Lisa Tolbert, Jean M. Lawrence, Robert Clemons, Michelle Maeva, Bonnie Sattler, Stuart Weinzimer, Brett Ives, Joan Bosson-Heenan, Craig Kollman, Dongyuan Xing, Judy Jackson, Michael Steffes, Jean M. Bucksa, Maren L. Nowicki, Carol Van Hale, Vicky Makky, Michael O'Grady, Elbert Huang, Anirban Basu, David O. Meltzer, Lan Zhao, Joyce Lee, Aaron J. Kowalski, Ruth S. Weinstock, Barbara J. Anderson, Davida Kruger, Lisa LaVange, Henry Rodriguez

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Despite improvements for management of type 1 diabetes (T1D), patients have difficulty achieving glycated hemoglobin (A1c) levels recommended by the Diabetes Control and Complications Trial (DCCT). Two multicenter randomized trials were conducted to evaluate benefit of using a continuous glucose monitor (CGM) with standard glucose monitoring for T1D management. The primary study evaluated benefits of CGM in 322 patients with A1c >7.0 %. The secondary study evaluated 129 patients with A1c <7.0 %. In the primary study, CGM resulted in improvements in A1c at 6 m in subjects >25 years, but not those <25. However, all subjects using CGM regularly showed benefit. Improved A1c did not come with increased severe hypoglycemia as seen in the DCCT, and benefit was sustained over 1 year. In the secondary study, CGM use helped subjects maintain target A1c levels with reduced exposure to biochemical hypoglycemia. The data collected allowed for other analyses of important factors in T1D management.

Original languageEnglish (US)
Pages (from-to)380-387
Number of pages8
JournalJournal of cardiovascular translational research
Volume5
Issue number4
DOIs
StatePublished - Aug 1 2012

Keywords

  • Continuous glucose monitoring
  • Glycated hemoglobin
  • Hypoglycemia
  • Psychosocial factors
  • Type 1 diabetes

Fingerprint Dive into the research topics of 'The landmark JDRF continuous glucose monitoring randomized trials: A look back at the accumulated evidence'. Together they form a unique fingerprint.

  • Cite this

    Tamborlane, W. V., Beck, R. W., Laffel, L., Ruedy, K. J., Chase, H. P., Fiallo-Scharer, R., Messer, L., Gage, V., Burdick, P., Milaszewski, K., Pratt, K., Bismuth, E., Keady, J., Lawlor, M., Buckingham, B., Wilson, D. M., Block, J., Benassi, K., Tsalikian, E., ... Rodriguez, H. (2012). The landmark JDRF continuous glucose monitoring randomized trials: A look back at the accumulated evidence. Journal of cardiovascular translational research, 5(4), 380-387. https://doi.org/10.1007/s12265-012-9364-9